{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:24:39Z","timestamp":1793053479853,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302613"],"award-info":[{"award-number":["82302613"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972750"],"award-info":[{"award-number":["81972750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The incidence of urothelial carcinoma (UC) ranks second among all urological cancers, accounting for over 90% of malignant tumors in bladder. Patients diagnosed with UC experience a lower quality of life due to rapid progression of the disease. Early and non-invasive detection is curial for diagnosing UC and improving patient outcomes. This study aimed to develop and validate a DNA methylation assay for the early detection and monitoring for UC, with a focus on its diagnostic and prognostic implications. The DNA methylation assay with real-time methylation specific polymerase chain reaction (RT-MSP) technique measures the methylation level of SOX1-OT and HIST1H4F in urine samples. A cohort comprising 436 patients diagnosed with UC or other urologic disease as well as 79 healthy patients was retrospectively utilized to evaluate this assay. Furthermore, UC patients who underwent surgery are included to assess its ability to detect recurrence. The DNA methylation assay demonstrated significantly increased methylation level in tumor tissues and a high positive rate in urine samples from UC patients. The methylation profile effectively distinguishes UC from other non-UC urologic disease, exhibiting a high sensitivity (85.2%) and specificity (90.0%) for UC diagnosis. Furthermore, the assay showed promising ability in differentiating UC patients based on tumor grade, malignancy potential, and disease stage. Additionally, the DNA methylation assay demonstrated a superior ability to detect UC recurrence with a high area under curve (AUC) of 0.979. This research proposes a novel DNA methylation assay with urine as sample for detection, representing a cost-efficient and non-invasive method for diagnosing and monitoring UC disease.<\/jats:p>","DOI":"10.1038\/s41598-025-14646-0","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T16:47:29Z","timestamp":1756140449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A urinary DNA methylation assay using two genes enables noninvasive detection and prognostic prediction in urothelial carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Dong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"14646_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"14646_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73 (1), 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"14646_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49 (3), 466\u2013465 (2006). discussion 75\u2009\u2013\u20097.","journal-title":"Eur. Urol."},{"issue":"5","key":"14646_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1309\/AJCP12MRVVHTCKEJ","volume":"133","author":"CC Pan","year":"2010","unstructured":"Pan, C. C. et al. Prognostic significance of the 2004 WHO\/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am. J. Clin. Pathol. 133 (5), 788\u2013795 (2010).","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"14646_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch, M. G. K. et al. Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur. Urol. 74 (6), 784\u2013795 (2018).","journal-title":"Eur. Urol."},{"issue":"3","key":"14646_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S van den Bosch","year":"2011","unstructured":"van den Bosch, S. & Alfred Witjes, J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur. Urol. 60 (3), 493\u2013500 (2011).","journal-title":"Eur. Urol."},{"issue":"2","key":"14646_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0022-5347(17)40763-4","volume":"141","author":"AJ Mariani","year":"1989","unstructured":"Mariani, A. J. et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J. Urol. 141 (2), 350\u2013355 (1989).","journal-title":"J. Urol."},{"issue":"4","key":"14646_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0090-4295(01)00919-0","volume":"57","author":"GD Grossfeld","year":"2001","unstructured":"Grossfeld, G. D. et al. Evaluation of asymptomatic microscopic hematuria in adults: the American urological association best practice policy\u2013part I: definition, detection, prevalence, and etiology. Urology 57 (4), 599\u2013603 (2001).","journal-title":"Urology"},{"issue":"10","key":"14646_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.6004\/jnccn.2016.0131","volume":"14","author":"PE Clark","year":"2016","unstructured":"Clark, P. E. et al. NCCN guidelines insights: bladder cancer, version 2.2016. J. Natl. Compr. Canc Netw. 14 (10), 1213\u20131224 (2016).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"14646_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","volume":"9","author":"JC Dudley","year":"2019","unstructured":"Dudley, J. C. et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 9 (4), 500\u2013509 (2019).","journal-title":"Cancer Discov"},{"key":"14646_CR11","doi-asserted-by":"publisher","first-page":"112699","DOI":"10.1016\/j.bios.2020.112699","volume":"171","author":"M MacGregor","year":"2021","unstructured":"MacGregor, M. et al. Cancer cell detection device for the diagnosis of bladder cancer from urine. Biosens. Bioelectron. 171, 112699 (2021).","journal-title":"Biosens. Bioelectron."},{"key":"14646_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2017.08.004","volume":"51","author":"A Chatterjee","year":"2018","unstructured":"Chatterjee, A., Rodger, E. J. & Eccles, M. R. Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biol. 51, 149\u2013159 (2018).","journal-title":"Semin Cancer Biol."},{"key":"14646_CR13","doi-asserted-by":"crossref","unstructured":"Baylin, S. B. & Jones, P. A. Epigenetic determinants of cancer. Cold Spring Harb Perspect. Biol. 8(9), a019505 (2016).","DOI":"10.1101\/cshperspect.a019505"},{"issue":"4","key":"14646_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","volume":"1","author":"JA Witjes","year":"2018","unstructured":"Witjes, J. A. et al. Performance of the bladder epicheck methylation test for patients under surveillance for Non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur. Urol. Oncol. 1 (4), 307\u2013313 (2018).","journal-title":"Eur. Urol. Oncol."},{"issue":"12","key":"14646_CR15","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","volume":"130","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J. Clin. Invest. 130 (12), 6278\u20136289 (2020).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"14646_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13148-021-01073-x","volume":"13","author":"W Ruan","year":"2021","unstructured":"Ruan, W. et al. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer. Clin. Epigenetics. 13 (1), 91 (2021).","journal-title":"Clin. Epigenetics"},{"key":"14646_CR17","doi-asserted-by":"publisher","first-page":"147352","DOI":"10.1016\/j.gene.2023.147352","volume":"866","author":"N Varol","year":"2023","unstructured":"Varol, N. et al. Methylation analysis of histone 4-related gene HIST1H4F and its effect on gene expression in bladder cancer. Gene 866, 147352 (2023).","journal-title":"Gene"},{"issue":"10","key":"14646_CR18","doi-asserted-by":"publisher","first-page":"e46297","DOI":"10.1371\/journal.pone.0046297","volume":"7","author":"T Reinert","year":"2012","unstructured":"Reinert, T. et al. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One. 7 (10), e46297 (2012).","journal-title":"PLoS One"},{"issue":"3","key":"14646_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.juro.2015.08.085","volume":"195","author":"KE van Kessel","year":"2016","unstructured":"van Kessel, K. E., Van Neste, L., Lurkin, I., Zwarthoff, E. C. & Van Criekinge, W. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J. Urol. 195 (3), 601\u2013607 (2016).","journal-title":"J. Urol."},{"key":"14646_CR20","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. A novel methylation marker NRN1 plus TERT and FGFR3 mutation using urine sediment enables the detection of urothelial bladder carcinoma. Cancers (Basel) 15(3), 615 (2023).","DOI":"10.3390\/cancers15030615"},{"issue":"7","key":"14646_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.urolonc.2018.04.001","volume":"36","author":"RQ Guo","year":"2018","unstructured":"Guo, R. Q. et al. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. Urol. Oncol. 36 (7), 342 (2018). e15- e23.","journal-title":"Urol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14646-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:56:39Z","timestamp":1757458599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14646"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14646-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Human Ethics Committee of the First Affiliated Hospital, Sun Yat-Sen University (Guangzhou, China), which follows the rules of Helsinki Declaration. Written informed consents were obtained from all participants. The ethical code of our study is [2022]549.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"31281"}}